In a multicenter observational study across 12 Italian oncology units, Dr. Alessandra Fabi and colleagues evaluated the real-life effectiveness of Trastuzumab Deruxtecan (T-DXd) in 39 patients with HER2-positive breast cancer and brain metastases.
The study demonstrated a strong intracranial response with an iORR of 59 percent, intracranial progression-free survival of 15.6 months, and global progression-free survival of 11.8 months. Disease control was achieved in nearly 95 percent of patients, and over three-quarters of patients were alive at 12 months.
This first real-world analysis highlights the promising efficacy and manageable safety profile of T-DXd beyond controlled trial settings.
Warm congratulations to the entire team for this impactful contribution to clinical practice.
Read the full article: https://lnkd.in/d-CRJxzx
